> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-82/
- Published: 2016-07-01T12:00:00.000Z
- Updated: 2026-09-14T21:12:59.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5136114

Waltham, Mass.-based **Morphic Therapeutic** says it has raised $51.5 million in a Series A venture financing to build on the shifting state of integrin receptors commonly found on the surface of about 90% of human cells from **Tim Springer** at Harvard Medical School. **GlaxoSmithKline’s** SR One venture group and **Pfizer** Venture Investment co-led the financing, along with Omega Funds, **AbbVie** Ventures, Tim Springer, Polaris Partners, Schrodinger and Shangpharma Investment Group.

**KaloBios Pharmaceuticals,** formerly run by **Martin Shkreli,** says it has emerged from bankruptcy and has acquired the rights to develop benznidazole for treating Chagas disease from **Savant Neglected Diseases** **LLC** for an upfront payment of $3 million, and warrants for Savant to buy 200,000 KaloBios common shares.

  
**Leo Pharma** has entered a strategic partnership with **AstraZeneca** and has acquired the global license to tralokinumab a potential new medicine, an anti-IL-13 monoclonal antibody that has completed a Phase 2b study for treating patients with atopic dermatitis and the exclusive license to brodalumab in Europe. The company says it will make an upfront payment to AstraZeneca of $115 million and will also pay up to $1 billion in commercially-related milestones and up to mid-teen tiered percentage royalties on product sales.

Australia’s **Mayne Pharma Group** has entered into an agreement to acquire 37 approved and five products with applications filed with FDA from **Teva Pharmaceutical** and **Allergan** for $652 million**.** The two companies were under pressure to divest to comply with FTC regulations in connection with Teva’s proposed acquisition of Allergan’s generic drug business.

**Lannett** is suing FDA in DC federal court over a 5/17 letter in which the agency rescinded its approval of the company’s ANDA for the oral cancer drug temozolomide (**Merck**’s Temodar). FDA says that the approval was “mistakenly granted.” At issue is the agency’s recent Warning Letter to China’s **Chongqing** **Lummy Pharmaceutical Co.,** which was to provide the active pharmaceutical ingredient for Lannett’s generic Temodar. The letter details CGMP violations found in an inspection and notes that the firm is under an import alert.